Mabion SA

  • Market Cap: Small Cap
  • Industry: Pharmaceuticals & Biotechnology
  • ISIN: PLMBION00016
PLN
7.39
-0.17 (-2.25%)
  • Price Points
  • Score
  • Mojo Parameters
  • Total Return
  • News and Corporate Actions
  • Key factors
  • Shareholding
  • Financials
  • CompanyCV
stock-summaryCompany CV
About Mabion SA stock-summary
stock-summary
Mabion SA
Pharmaceuticals & Biotechnology
Mabion SA is a Poland-based company engaged in the research and development of biotechnological and biopharmaceutical medicinal products. Mabion SA was founded by four pharmaceutical companies, including Celon Pharma Ltd, Polfarmex Co, Genexo Ltd and IBSS Biomed Co, as well as two companies focused on research and development in biotechnology field, including BioCentrum Ltd and Biotech Consulting Ltd. The Company specializes in the humanized monoclonal antibodies (mAbs) technology, a new generation of biotechnological drugs. It focuses on oncology drugs used to treat blood cancer, lymphomas and leukemias, rheumatoid arthrisis, as well as breast cancer. It operates its own Research and Development Center in the Special Economical Zone in Lodz, Poland.
Company Coordinates stock-summary
Company Details
Ul. gen. Mariana Langiewicza 60 , KONSTANTYNOW LODZKI None : 95-050
stock-summary
Tel: 48 42 207789048 575 896041
stock-summary
Registrar Details
stock-recommendation Shareholding
Shareholding Snapshotstock-summary
Icon
No data for shareholding present.
Shareholding Compare (%holding) stock-summary
Icon
No data for shareholding present.
stock-summary Board of Directorsstock-summary
Management
Designation
Mr. Krzysztof Kaczmarczyk
Chairman of the Supervisory Board
Dr. Maciej Wieczorek
Vice Chairman of the Supervisory Board
Mr. David James
Independent Member of the Supervisory Board
Mr. Robert Konski
Independent Member of the Supervisory Board
Prof. Dr. Tadeusz Pietrucha
Independent Member of the Supervisory Board
Mr. Jozef Banach
Member of the Supervisory Board
Mr. Jacek Nowak
Member of the Supervisory Board
stock-recommendation Stock DNA
Revenue and Profits:
Net Sales:
3 Million
(Quarterly Results - Mar 2025)
Net Profit:
-15 Million
stock-summary
Industry

Pharmaceuticals & Biotechnology

stock-summary
Market cap

PLN 127 Million (Small Cap)

stock-summary
P/E

NA (Loss Making)

stock-summary
Industry P/E

NA

stock-summary
Dividend Yield

0.00%

stock-summary
Debt Equity

-0.04

stock-summary
Return on Equity

-85.35%

stock-summary
Price to Book

1.81